|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||18.49 - 19.13|
|52 Week Range||15.40 - 26.75|
|Beta (5Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.64|
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.
The analysts covering Nektar Therapeutics ( NASDAQ:NKTR ) delivered a dose of negativity to shareholders today, by...